Suppr超能文献

脊髓刺激治疗慢性胰腺炎内脏痛。

Spinal cord stimulation for visceral pain from chronic pancreatitis.

机构信息

Pain Management Department, Anesthesia Institute, Cleveland Clinic, Cleveland, Ohio, USA.

出版信息

Neuromodulation. 2011 Sep-Oct;14(5):423-6; discussion 426-7. doi: 10.1111/j.1525-1403.2011.00381.x. Epub 2011 Aug 19.

Abstract

BACKGROUND AND OBJECTIVES

Spinal cord stimulation (SCS) may reduce pain scores and improve function in patients with various chronic abdominal pain syndromes including chronic pancreatitis. Here described is a large clinical experience in SCS for severe chronic pancreatitis.

METHODS

SCS was trialed in 30 patients with chronic pancreatitis. SCS trials lasted 7-14 days (median 9 days). SCS lead tips were mostly positioned at the T5 (N= 10) or T6 (N= 10) vertebral level.

RESULTS

Twenty-four patients (80%) reported at least 50% pain relief on completion of the trial. Among these, pre-trial visual analog scale (VAS) pain scores averaged 8 ± 1.6 (standard deviation) and opioid use averaged 165 ± 120 mg morphine sulfate equivalents. During the trial, VAS pain scores decreased to 3.67 ± 2 cm (p < 0.001, Mann-Whitney Rank Sum Test) and opioid use decreased to 105 ± 101 mg morphine equivalent a day. Six patients failed the trial; one was lost to follow-up; in three patients after the implantation, the system had to be removed due to infection or lead migration; and 20 were followed for the whole year. For 20 patients followed for the whole year, VAS pain scores remained low (3.6 ± 2 cm; p < 0.001) at one year, as did opioid use (48.6 ± 58 mg morphine equivalents).

CONCLUSIONS

SCS may be a useful therapeutic option for patients with severe visceral pain from chronic pancreatitis. Prospective trial is warranted.

摘要

背景与目的

脊髓刺激(SCS)可能会降低各种慢性腹痛综合征(包括慢性胰腺炎)患者的疼痛评分并改善其功能。这里描述的是 SCS 在严重慢性胰腺炎中的大量临床经验。

方法

对 30 例慢性胰腺炎患者进行了 SCS 试验。SCS 试验持续 7-14 天(中位数 9 天)。SCS 导联尖端大多位于 T5(N=10)或 T6(N=10)椎骨水平。

结果

24 例患者(80%)在试验结束时报告至少 50%的疼痛缓解。其中,术前视觉模拟量表(VAS)疼痛评分平均为 8±1.6(标准差),阿片类药物使用平均为 165±120mg 硫酸吗啡当量。在试验过程中,VAS 疼痛评分降至 3.67±2cm(p<0.001,Mann-Whitney 秩和检验),阿片类药物使用量降至 105±101mg 吗啡当量/天。6 例患者试验失败;1 例失访;3 例患者在植入后因感染或导联移位而不得不移除系统;20 例患者接受了全年随访。对于 20 例接受全年随访的患者,VAS 疼痛评分在一年后仍然较低(3.6±2cm;p<0.001),阿片类药物使用量(48.6±58mg 吗啡当量)也保持不变。

结论

SCS 可能是治疗慢性胰腺炎严重内脏疼痛患者的有用治疗选择。需要进行前瞻性试验。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验